Workflow
Viking Therapeutics(VKTX)
icon
Search documents
After Falling 68%, Where Will This Weight-Loss Drug Stock Be in 2 Years? History Shows Massive Gains Ahead.
The Motley Fool· 2025-07-19 10:09
Core Viewpoint - Viking Therapeutics has experienced significant stock volatility, with shares down nearly 60% since October of last year and 68% from early 2024 highs, despite a promising drug pipeline [1][2][3] Company Overview - Viking Therapeutics is a pre-revenue biopharma company with a market cap of $3.5 billion, focusing on developing treatments for rare metabolic and endocrine disorders [3][4] - The company is currently testing four different drugs across five clinical trials, with its lead candidate VK2735, an injectable anti-obesity drug, in phase 3 testing [4][5] Market Dynamics - The stock's volatility is attributed to market reactions to the drug's development progress, with investors often overreacting to news, leading to sharp price fluctuations [7][8] - Historical patterns in biopharma stocks suggest that significant price drops can precede a recovery, especially when the underlying drug shows potential [2][14] Competitive Landscape - Viking's VK2735 competes with established obesity drugs from Novo Nordisk and Eli Lilly, but there is potential for market share due to consumer willingness to try alternatives [15][16] - The global weight-loss drug market is projected to grow from $15 billion to $150 billion by 2035, indicating substantial growth opportunities for Viking Therapeutics [16] Future Outlook - The stock is expected to rally within a two-year timeframe as meaningful updates on VK2735's phase 3 testing are anticipated [17] - Concerns regarding the cost of manufacturing VK2735 in both injectable and oral forms may be overstated, given the projected demand in the market [18]
Viking Therapeutics, Inc. (VKTX) Outperforms Broader Market: What You Need to Know
ZACKS· 2025-07-17 22:45
Company Performance - Viking Therapeutics, Inc. (VKTX) experienced a daily increase of +1.39% to $32.07, outperforming the S&P 500's gain of 0.54% [1] - Prior to the latest trading session, the company's shares had risen by 20.36%, contrasting with the Medical sector's decline of 2.12% and the S&P 500's increase of 4.2% [1] Earnings Forecast - The upcoming earnings release is anticipated to show an EPS of -$0.44, reflecting a 120% decline compared to the same quarter last year [2] - For the full year, the Zacks Consensus Estimates predict an EPS of -$1.86 and revenue of $25 million, indicating changes of -84.16% and 0% respectively from the previous year [2] Analyst Estimates - Recent changes to analyst estimates for Viking Therapeutics should be monitored, as they often indicate short-term business trends [3] - Positive estimate revisions are viewed as a sign of optimism regarding the business outlook [3] Zacks Rank System - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has shown a strong track record, with 1 stocks averaging an annual return of +25% since 1988 [5] - Currently, Viking Therapeutics holds a Zacks Rank of 3 (Hold), with no changes in the consensus EPS projection over the past 30 days [5] Industry Overview - The Medical - Biomedical and Genetics industry, which includes Viking Therapeutics, ranks in the top 34% of over 250 industries according to the Zacks Industry Rank [6] - The Zacks Industry Rank measures the strength of individual industry groups based on the average Zacks Rank of stocks within those groups [6]
Viking Therapeutics to Report Financial Results for Second Quarter 2025 on July 23, 2025
Prnewswire· 2025-07-16 20:05
Company Overview - Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders [3] - The company leverages its expertise in metabolism to create innovative therapeutics aimed at improving patients' lives [3] Clinical Programs - Viking's clinical programs include VK2735, a dual agonist of GLP-1 and GIP receptors, currently evaluated in a Phase 3 obesity program with two trials (VANQUISH-1 and VANQUISH-2) [3] - VK2735 has shown an encouraging safety and tolerability profile along with positive clinical benefits in Phase 1 and Phase 2 trials [3] - An oral formulation of VK2735 is also being evaluated in a Phase 2 trial for obesity [3] - VK2809, a small molecule selective thyroid hormone receptor beta agonist, has achieved primary and secondary endpoints in a Phase 2b study for NASH and fibrosis [3] - In a Phase 2a trial for NAFLD and elevated LDL-C, VK2809 demonstrated statistically significant reductions in LDL-C and liver fat compared to placebo [3] - The company is developing dual amylin and calcitonin receptor agonists (DACRAs) for obesity and metabolic disorders [3] - VK0214, another small molecule selective thyroid hormone receptor beta agonist, is in development for X-ALD and has shown safety and significant reductions in VLCFAs in a Phase 1b trial [3] Upcoming Events - Viking Therapeutics will release its financial results for Q2 2025 after market close on July 23, 2025 [1] - A conference call to discuss these results and corporate updates is scheduled for July 23, 2025, at 4:30 p.m. Eastern Time [2]
Better Growth Buy: Eli Lilly vs. Viking Therapeutics
The Motley Fool· 2025-07-07 07:45
Though you may think "tech stocks" when someone mentions growth, you actually can find growth stocks throughout a wide variety of industries. Even those like pharmaceuticals, often known for the steadiness of their earnings, may, through certain specialty areas, offer you the opportunity for explosive growth. And today, the perfect example is weight loss drugs. Today's $28 billion weight loss drug market is on track to reach nearly $100 billion by 2030, according to Goldman Sachs Research, offering companie ...
Viking Therapeutics (VKTX) Earnings Call Presentation
2025-07-04 12:11
VK2735 (GLP-1/GIP Dual Agonist) for Obesity - The VENTURE Phase 2 obesity study achieved its primary endpoint, demonstrating a significant reduction in body weight after 13 weeks of treatment[7, 43] - In the VENTURE study, patients receiving VK2735 experienced up to a 14.7% reduction in body weight from baseline after 13 weeks[44, 61] - Up to 88% of patients in the VENTURE study experienced ≥10% weight loss at the 15mg dose after 13 weeks[50, 51] - Oral VK2735 Phase 1 study showed a dose-dependent reduction in body weight, with a significant reduction of 5.3% versus placebo at the highest dose after 28 days[74, 97] - The company plans to initiate a Phase 2 trial for oral VK2735 in obesity in the second half of 2024[7, 98] VK2809 (Selective Thyroid Receptor-β Agonist) for NASH/MASH - The VOYAGE Phase 2b trial achieved its primary endpoint, demonstrating a robust reduction in liver fat[7, 125] - In the VOYAGE study, patients experienced up to a 55% median reduction in liver fat at 12 weeks[113, 114] - Up to 85% of VK2809 patients experienced a response, defined as a ≥30% decrease in liver fat at Week 12 in the VOYAGE study[116, 117] VK0214 (Selective Thyroid Receptor-β Agonist) for X-ALD - VK0214 Phase 1 study demonstrated LDL-C reductions, with data indicating approximately a 20% reduction from baseline[136, 137] - A Phase 1b study of VK0214 in patients with X-linked adrenoleukodystrophy is ongoing, with data expected in the second quarter of 2024[7] Financial Status - As of December 31, 2023, the company's cash and short-term investments totaled $362.079 million[141] - The company's cash burn year-to-date as of December 31, 2023, was $76.835 million[141] - A follow-on offering in the first quarter of 2024 yielded gross proceeds of $630 million[141]
Why I Think Viking Therapeutics Is an Asymmetric Growth Opportunity
The Motley Fool· 2025-07-04 08:30
Core Insights - The biotech industry, particularly in obesity treatment, is experiencing a significant opportunity with Viking Therapeutics' VK2735, a dual GLP-1/GIP receptor agonist, which has shown promising results in clinical trials [3][4][11] - Viking's VK2735 has demonstrated a 14.7% weight loss at 13 weeks with a tolerability profile that matches placebo, setting it apart from competitors like Wegovy and Zepbound, which have higher discontinuation rates [3][4][5][11] - The obesity drug market is projected to reach $200 billion by 2030, and Viking's oral formulation could potentially expand the market by attracting patients who avoid current treatments due to side effects [5][6][21] Company Overview - Viking Therapeutics is developing VK2735, which has shown a 13% discontinuation rate, comparable to placebo, indicating a strong safety profile [4][6] - The company has secured a $150 million manufacturing deal with CordenPharma, ensuring capacity for 100 million autoinjectors and 1 billion tablets annually, which alleviates manufacturing concerns common in small-cap biotechs [18][19] Market Dynamics - Viking's stock has seen a significant decline of 64% from its 52-week high, reflecting broader market challenges rather than company-specific issues [9][10] - Institutional investors are showing confidence in Viking, with significant bullish positions being accumulated, contrasting with rising short interest among retail investors [13][16] Investment Opportunity - The upcoming phase 2 oral data release is anticipated to present an asymmetric investment opportunity, with potential for the oral formulation to achieve efficacy similar to injectables [20][21] - Current market valuation of Viking at $3 billion is significantly lower than the value created by successful GLP-1 drugs, suggesting a potential for revaluation if VK2735's oral formulation proves effective [21][24] - The market is currently pricing Viking as a high-risk investment, but the data suggests a more favorable outlook, with a reasonable probability of success for VK2735 being much higher than the market's implied odds [23][24][25]
2 Beaten-Down Stocks With Massive Upside Potential
The Motley Fool· 2025-07-03 11:00
Group 1: CRISPR Therapeutics - CRISPR Therapeutics has developed Casgevy, the first gene-editing medicine approved using the CRISPR technique, but the stock has been on a downward trend since 2021 due to clinical progress, complexity of therapy administration, and unprofitability [3][4] - The company is targeting challenging areas such as type 1 diabetes and hard-to-treat cancers, with expected data readouts for ongoing clinical trials as early as this year, which could positively impact stock performance [5] - Casgevy has significant financial implications, with a treatment cost of $2.2 million in the U.S. and an estimated 60,000 patients in target geographies, indicating blockbuster potential [9] Group 2: Viking Therapeutics - Viking Therapeutics gained attention after strong phase 2 results for VK2735, an investigational weight management therapy, but has seen stock performance decline as investors took profits [10] - The anti-obesity therapy market is rapidly growing, and Viking's VK2735 has shown promising mid-stage data, with an oral formulation currently in Phase 2 studies [11] - Viking Therapeutics has a robust pipeline, including VK2809 for metabolic dysfunction-associated steatohepatitis entering phase 3 studies and VK0214 for X-linked adrenoleukodystrophy, which has received orphan drug designation [12][13]
10 Incredible Growth Stocks Poised for Long-Term Gains
The Motley Fool· 2025-07-02 10:30
Core Insights - Growth stocks are experiencing significant volatility in 2025 due to geopolitical issues, high interest rates, AI developments, and valuation concerns [1] - Despite the focus on the "Magnificent Seven," there are transformative companies reaching key inflection points that present compelling investment opportunities [1] Company Summaries - **Oscar Health (OSCR)**: Achieved 42% revenue growth to $3 billion in Q1 2025, with membership exceeding 2 million and net income rising to $275 million from $177 million year over year [3][4] - **Equinix (EQIX)**: Operates 260 data centers globally, but stock dropped 16% due to lower-than-expected growth guidance of 5% to 9% annual adjusted funds from operations through 2029 [5][6] - **Viking Therapeutics (VKTX)**: Developing a potential obesity drug VK2735, which showed up to 14.7% weight loss in phase 2 trials; the obesity drug market is projected to reach $130 billion by 2030 [7][8] - **BigBear.ai (BBAI)**: Provides AI-powered analytics with a revenue growth of 2% year over year to $158 million in 2024; trading at 10.6 times trailing sales, offering exposure to practical AI applications [9][10] - **Rocket Lab (RKLB)**: Posted 32% revenue growth to $123 million in Q1 2025, with a focus on its Neutron rocket debuting in late 2025 and a $1.45 billion federal contract [11][12] - **Archer Aviation (ACHR)**: Progressing through FAA certification for electric vertical takeoff aircraft, targeting commercial operations in Abu Dhabi by Q4 2025, with a total addressable market for urban air mobility potentially reaching $1 trillion by 2040 [13][14] - **Joby Aviation (JOBY)**: In the final phase of FAA certification, plans to carry passengers in Dubai by late 2025 or early 2026, backed by a $500 million investment from Toyota [15][16] - **Navitas Semiconductor (NVTS)**: Focused on gallium nitride power semiconductors, despite a 40% revenue decline to $14 million in Q1 2025, positioned for growth in AI data centers and EVs [17] - **Intuitive Machines (LUNR)**: First commercial company to land on the moon, with Q1 2025 revenue of $62.5 million and a contracted backlog of $272 million [18][19] - **Palantir (PLTR)**: Experiencing explosive adoption of its AI Platform, with U.S. commercial revenue surging 71% and government revenue stable at $373 million quarterly [20][21] Market Trends - These companies are targeting massive markets, achieving operational inflection points, and trading at reasonable valuations relative to their potential [22] - The focus on these growth stocks may provide compelling risk-reward opportunities for investors looking beyond the more prominent tech names [23]
3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking
MarketBeat· 2025-06-29 12:36
Core Insights - Biotechnology stocks, with exceptions like Novo Nordisk and Eli Lilly, faced challenges in attracting investment capital in 2024 due to a high interest rate environment [1] - The FDA's cautious approach to drug approvals, particularly in breakthrough areas like gene therapy, has impacted large-cap drug companies [2] - The biotech industry is leveraging AI to enhance efficiencies and accelerate drug development, particularly in precision medicine [3] Company-Specific Insights - **Iovance Biotherapeutics**: Received FDA approval for Amtagvi, the first TIL therapy for solid tumors, transitioning from clinical stage to revenue generation. However, the stock is down 75.8% in 2025, with concerns over slow sales and cash burn projected at $300 million for the year [5][6][8] - **Neurocrine Biosciences**: Projecting revenue between $2.5 billion and $2.6 billion in 2025 from its Ingrezza therapy. The approval of Crenessity for congenital adrenal hyperplasia could boost revenue significantly, with peak U.S. sales estimated at $800 million to $1 billion [9][10][11] - **Viking Therapeutics**: Stock is down 33% as it awaits Phase 2 results for its GLP-1 candidate VK2735. The company faces competition from Eli Lilly and has significant short interest, but claims of durable weight loss could provide a competitive edge [13][14][15]
Why This Weight Loss Drug Company's Stock Surged Today
The Motley Fool· 2025-06-26 17:59
Group 1 - Viking Therapeutics' shares increased by 6.3% following the initiation of a phase 3 trial for VK2375, a treatment for metabolic disorders including obesity [1] - The market is optimistic about VK2375 due to its potential as a dual GLP-1/GIP receptor agonist, similar to Eli Lilly's successful weight loss drug Zepbound [2][7] - Viking Therapeutics has a market capitalization of $3.2 billion and may face competition from established players unless it can demonstrate superior efficacy in the phase 3 trial [3] Group 2 - The oral formulation of VK2375 presents significant convenience and accessibility advantages over subcutaneous options, which could attract larger pharmaceutical companies for potential acquisition [4] - Phase 2 trial results for the oral formulation are anticipated later this year, which could influence investor sentiment and market positioning [6] - The competitive landscape is intensifying, with Novo Nordisk seeking FDA approval for an oral formulation of Wegovy and Eli Lilly reporting positive phase 3 results for an oral GLP-1 agonist [6]